Evidence mapPaperPMID 41721152Full record

ReviewInternational journal of clinical oncology2026

Statistics and epidemiology of inflammatory bowel disease-associated colorectal neoplasia.

Takahide Shinagawa, Satoshi Okada, Hiroshi Shiratori, Yuichi Tachikawa, Yuzo Harada, Yuzo Nagai, Yuichiro Yokoyama, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki and 2 more

Abstract readReview
In one paragraph

Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takahide ShinagawaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.ORCID http://orcid.org/0000-0003-3790-7047
Satoshi OkadaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Hiroshi ShiratoriDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yuichi TachikawaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yuzo HaradaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yuzo NagaiDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Yuichiro YokoyamaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Shigenobu EmotoDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Koji MuronoDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Kazuhito SasakiDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Hiroaki NozawaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Soichiro IshiharaDepartment of Surgical Oncology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. soichiro.ishihara@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are associated with an increased risk of intestinal neoplasia, representing a major long-term complication of chronic inflammation. This review summarizes the recent epidemiological trends and clinicopathological features of IBD-associated colorectal cancer (CRC) and dysplasia in UC and CD. In UC, the cumulative risk of CRC has declined in recent decades, possibly reflecting improvements in medical management and surveillance strategies. However, long disease duration, extensive colitis, concomitant primary sclerosing cholangitis, prior dysplasia, and family history of CRC remain major risk factors. UC-associated neoplasia (UCAN) typically presents as flat lesions with indistinct margins, often accompanied by surrounding dysplasia and frequently exhibits multifocal or infiltrative histological features. The prognosis of UCAN is reportedly poorer than that of sporadic CRC, particularly in advanced stages. In CD, although the overall incidence of neoplasia is lower, the relative risk of colorectal and small intestinal cancer remains significantly higher than in the general population. Geographic variations are notable, with anorectal and fistula-associated carcinomas being most prevalent in East Asia. Risk factors for CD-associated neoplasia (CDAN) include long-standing and early-onset disease, extensive colonic involvement, strictures, and a family history of CRC. Survival outcome of CDAN is worse than that of sporadic CRC, with a higher local recurrence rate. IBD-associated intestinal neoplasia exhibits distinct epidemiological and clinicopathological profiles compared with sporadic CRC. Recent nationwide multicenter studies from Japan provide important insights into UCAN and CDAN, underscoring the importance of region-specific understanding to optimize surveillance and management strategies.

Indexed as

Colitis, UlcerativeColorectal NeoplasmsCrohn DiseaseInflammatory Bowel DiseasesHumansIncidencePrognosisRisk FactorsCD-associated neoplasiaCrohn’s diseaseInflammatory bowel diseasesUC-associated neoplasiaUlcerative colitis

Identifiers

PMID41721152
PMCPMC13018043

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.